Skip to main content
. Author manuscript; available in PMC: 2010 Mar 12.
Published in final edited form as: J Cardiometab Syndr. 2008 Spring;3(2):111–114. doi: 10.1111/j.1559-4572.2008.07552.x

Table 1.

Case patient’s changes in metabolic parameters over time.

Metabolic Parameter 3/7/2000 4/3/2001 2/3/2003 7/22/2004 1/27/2005 7/11/2006 2/22/2007
Atorvastatin begun Pravastin/fenofibrate begun Pravastin/fenofibrate increased
Body Weight (kg) 77.6 86.6 86.1 98.8 105.2 101.2 102.5
Body Mass Index (kg/m2) 23.2 25.8 25.7 29.5 31.4 30.2 30.6
Heart Rate (beats/minute) 68 84 82 72 72 66 74
Blood Pressure (mm Hg) 130/70 108/80 130/90 132/88 118/74 120/82 106/70
Antiretroviral Regimen Indinavir
Lamivudine
Zidovudine		 Nevirapine
Abacavir
Stavudine		 Nevirapine
Abacavir
Stavudine
Tenofovir		 Fosamprenavir
Ritonavir
Abacavir
Lamivudine
Didanosine		 Fosamprenavir
Ritonavir
Abacavir
Lamivudine
Didanosine		 Fosamprenavir
Ritonavir
Abacavir
Emtricitabine
Didanosine		 Didanosine
Epzicom
Abacavir
Emtricitabine
Didanosine
CD4 Cell Count (cells/mm3) 493 672 735 1285 794 787 938
HIV RNA Level (copies/mL) 36811 <75 4353 <75 <75 2025 993
Fasting Glucose (mg/dL) 90 90 91 81 119 127 93
Total Cholesterol (mg/dL) 180 201 126 220 244 142 188
LDL (mg/dL) NR Not calculated* 39 Not calculated* Not calculated* 53 117
Triglycerides (mg/dL) 165 500 298 820 1501 258 174

HIV=human immunodeficiency virus; HDL=high density lipoprotein; LDL=low-density lipoprotein; NR=not reported

*

LDL is unable to be calculated when serum triglyceride level exceeds 400 mg/dL.